Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| BCG Vaccine | 4 | 2022 | 57 | 2.140 |
Why?
|
| Infant, Newborn | 24 | 2026 | 1418 | 1.730 |
Why?
|
| Vaccination | 7 | 2025 | 377 | 1.720 |
Why?
|
| Vaccines | 4 | 2025 | 96 | 1.230 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2021 | 70 | 1.160 |
Why?
|
| Hypersensitivity | 5 | 2021 | 72 | 1.130 |
Why?
|
| Mast Cells | 12 | 2012 | 51 | 0.970 |
Why?
|
| Intensive Care Units, Neonatal | 4 | 2025 | 99 | 0.900 |
Why?
|
| Immunization Schedule | 2 | 2025 | 22 | 0.890 |
Why?
|
| Hepatitis B Vaccines | 1 | 2025 | 16 | 0.890 |
Why?
|
| Pneumococcal Vaccines | 1 | 2025 | 22 | 0.880 |
Why?
|
| Infant, Premature | 3 | 2023 | 198 | 0.770 |
Why?
|
| Immunity, Innate | 4 | 2021 | 821 | 0.760 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2022 | 26 | 0.730 |
Why?
|
| Viral Vaccines | 1 | 2022 | 56 | 0.720 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2022 | 39 | 0.710 |
Why?
|
| Infant | 10 | 2025 | 1692 | 0.710 |
Why?
|
| Activation, Metabolic | 1 | 2021 | 3 | 0.700 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2021 | 80 | 0.700 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2024 | 20 | 0.680 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2021 | 28 | 0.670 |
Why?
|
| Delivery, Obstetric | 1 | 2021 | 59 | 0.650 |
Why?
|
| Autistic Disorder | 3 | 2012 | 154 | 0.640 |
Why?
|
| Monocytes | 2 | 2024 | 356 | 0.630 |
Why?
|
| Premature Birth | 3 | 2021 | 113 | 0.630 |
Why?
|
| Microbial Viability | 1 | 2020 | 56 | 0.620 |
Why?
|
| RNA, Bacterial | 1 | 2020 | 73 | 0.610 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 239 | 0.610 |
Why?
|
| Cytokines | 3 | 2021 | 951 | 0.600 |
Why?
|
| Inflammation | 4 | 2021 | 1187 | 0.590 |
Why?
|
| Breast Feeding | 4 | 2025 | 166 | 0.550 |
Why?
|
| Nervous System Malformations | 1 | 2017 | 12 | 0.540 |
Why?
|
| Microcephaly | 1 | 2017 | 15 | 0.540 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 17 | 0.540 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 47 | 0.520 |
Why?
|
| Zika Virus Infection | 1 | 2017 | 38 | 0.520 |
Why?
|
| Humans | 45 | 2026 | 65168 | 0.510 |
Why?
|
| Brain | 2 | 2017 | 1601 | 0.490 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 164 | 0.490 |
Why?
|
| Biomarkers | 4 | 2025 | 1479 | 0.480 |
Why?
|
| Guideline Adherence | 1 | 2017 | 307 | 0.450 |
Why?
|
| Neurotensin | 3 | 2012 | 13 | 0.440 |
Why?
|
| Pregnancy | 7 | 2025 | 2370 | 0.440 |
Why?
|
| Child Development Disorders, Pervasive | 2 | 2011 | 42 | 0.420 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 729 | 0.390 |
Why?
|
| DNA Methylation | 2 | 2026 | 302 | 0.390 |
Why?
|
| Neonatal Sepsis | 2 | 2024 | 4 | 0.370 |
Why?
|
| Fetal Diseases | 1 | 2012 | 22 | 0.370 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 706 | 0.370 |
Why?
|
| Female | 22 | 2026 | 33982 | 0.360 |
Why?
|
| Encephalitis | 1 | 2012 | 37 | 0.360 |
Why?
|
| Mastocytosis | 1 | 2011 | 2 | 0.360 |
Why?
|
| Neutrophils | 2 | 2024 | 390 | 0.340 |
Why?
|
| Stress, Physiological | 2 | 2012 | 208 | 0.330 |
Why?
|
| Pandemics | 4 | 2022 | 675 | 0.330 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 325 | 0.320 |
Why?
|
| Substance P | 5 | 2012 | 43 | 0.290 |
Why?
|
| Child Development | 2 | 2020 | 87 | 0.290 |
Why?
|
| Male | 17 | 2026 | 31020 | 0.290 |
Why?
|
| Adjuvants, Immunologic | 3 | 2025 | 235 | 0.280 |
Why?
|
| Systems Biology | 2 | 2025 | 36 | 0.260 |
Why?
|
| Dermatitis, Atopic | 3 | 2012 | 29 | 0.250 |
Why?
|
| Gene Expression Profiling | 3 | 2026 | 794 | 0.240 |
Why?
|
| Proteomics | 3 | 2023 | 291 | 0.240 |
Why?
|
| Milk, Human | 2 | 2025 | 99 | 0.240 |
Why?
|
| Corticotropin-Releasing Hormone | 4 | 2012 | 38 | 0.230 |
Why?
|
| Metabolome | 1 | 2025 | 36 | 0.220 |
Why?
|
| Lipid A | 1 | 2025 | 67 | 0.220 |
Why?
|
| AIDS Vaccines | 1 | 2025 | 72 | 0.210 |
Why?
|
| Stakeholder Participation | 1 | 2024 | 29 | 0.210 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2025 | 130 | 0.210 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 93 | 0.200 |
Why?
|
| Cell Degranulation | 3 | 2012 | 23 | 0.200 |
Why?
|
| Fentanyl | 1 | 2024 | 66 | 0.200 |
Why?
|
| Lymphocytes | 1 | 2024 | 204 | 0.200 |
Why?
|
| Proteome | 2 | 2023 | 152 | 0.200 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 32 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2026 | 440 | 0.190 |
Why?
|
| Promoter Regions, Genetic | 1 | 2026 | 687 | 0.190 |
Why?
|
| Microbiota | 1 | 2025 | 168 | 0.190 |
Why?
|
| Adult | 8 | 2025 | 17331 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2012 | 234 | 0.190 |
Why?
|
| Drug Overdose | 1 | 2024 | 122 | 0.190 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2026 | 660 | 0.180 |
Why?
|
| Child | 6 | 2022 | 4606 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 729 | 0.180 |
Why?
|
| Sepsis | 1 | 2026 | 295 | 0.180 |
Why?
|
| Placenta | 1 | 2022 | 69 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 509 | 0.180 |
Why?
|
| Lactation | 1 | 2022 | 78 | 0.180 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 102 | 0.170 |
Why?
|
| Retrospective Studies | 3 | 2025 | 6859 | 0.170 |
Why?
|
| Risk Factors | 3 | 2021 | 5425 | 0.170 |
Why?
|
| T-Lymphocytes | 1 | 2026 | 1008 | 0.170 |
Why?
|
| Transcriptome | 1 | 2024 | 399 | 0.170 |
Why?
|
| Infant, Low Birth Weight | 1 | 2021 | 59 | 0.170 |
Why?
|
| Acute-Phase Proteins | 1 | 2020 | 35 | 0.160 |
Why?
|
| Immunoglobulins | 1 | 2020 | 74 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 601 | 0.160 |
Why?
|
| Gestational Age | 1 | 2021 | 192 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 465 | 0.160 |
Why?
|
| Bulgaria | 1 | 2020 | 1 | 0.160 |
Why?
|
| Denmark | 1 | 2020 | 18 | 0.160 |
Why?
|
| Japan | 1 | 2020 | 64 | 0.160 |
Why?
|
| Complement System Proteins | 1 | 2020 | 110 | 0.160 |
Why?
|
| Mycobacterium bovis | 1 | 2020 | 29 | 0.150 |
Why?
|
| Gambia | 3 | 2026 | 6 | 0.150 |
Why?
|
| Papua New Guinea | 3 | 2026 | 8 | 0.150 |
Why?
|
| HIV-1 | 1 | 2025 | 704 | 0.150 |
Why?
|
| Immune System | 1 | 2020 | 132 | 0.150 |
Why?
|
| India | 1 | 2020 | 163 | 0.150 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 197 | 0.150 |
Why?
|
| Immunologic Memory | 1 | 2021 | 282 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2025 | 3310 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 801 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2022 | 308 | 0.140 |
Why?
|
| RNA, Messenger | 6 | 2020 | 1573 | 0.140 |
Why?
|
| HIV Infections | 1 | 2025 | 953 | 0.140 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2017 | 30 | 0.130 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 3 | 2012 | 27 | 0.130 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2017 | 48 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 804 | 0.130 |
Why?
|
| Zika Virus | 1 | 2017 | 37 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 70 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2021 | 464 | 0.130 |
Why?
|
| Skin | 2 | 2010 | 421 | 0.130 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 528 | 0.130 |
Why?
|
| Hospice Care | 1 | 2017 | 75 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2019 | 399 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2017 | 222 | 0.110 |
Why?
|
| Massachusetts | 1 | 2021 | 2140 | 0.110 |
Why?
|
| Protein Interaction Maps | 2 | 2026 | 35 | 0.100 |
Why?
|
| Interleukin-9 | 1 | 2012 | 1 | 0.090 |
Why?
|
| Receptors, Interleukin-9 | 1 | 2012 | 1 | 0.090 |
Why?
|
| Secretory Vesicles | 1 | 2012 | 24 | 0.090 |
Why?
|
| Epigenesis, Genetic | 2 | 2026 | 407 | 0.090 |
Why?
|
| Mitochondria | 2 | 2012 | 408 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2012 | 2059 | 0.080 |
Why?
|
| beta-Endorphin | 1 | 2010 | 9 | 0.080 |
Why?
|
| Stress, Psychological | 2 | 2012 | 473 | 0.080 |
Why?
|
| DNA, Mitochondrial | 1 | 2010 | 86 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 213 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2010 | 184 | 0.080 |
Why?
|
| Interleukins | 1 | 2010 | 87 | 0.080 |
Why?
|
| Psoriasis | 1 | 2010 | 59 | 0.070 |
Why?
|
| Metabolomics | 2 | 2019 | 63 | 0.070 |
Why?
|
| Age Factors | 2 | 2024 | 1584 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 2241 | 0.070 |
Why?
|
| Patient Discharge | 2 | 2022 | 519 | 0.070 |
Why?
|
| Prognosis | 2 | 2024 | 1783 | 0.070 |
Why?
|
| Asthma | 1 | 2012 | 481 | 0.060 |
Why?
|
| United States | 1 | 2020 | 8209 | 0.060 |
Why?
|
| Glucosides | 1 | 2025 | 15 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2023 | 2618 | 0.060 |
Why?
|
| Boston | 1 | 2025 | 258 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2024 | 101 | 0.050 |
Why?
|
| Animals | 5 | 2026 | 21292 | 0.050 |
Why?
|
| HIV Antibodies | 1 | 2025 | 146 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 292 | 0.050 |
Why?
|
| Calcium | 3 | 2012 | 583 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2024 | 129 | 0.050 |
Why?
|
| Trachea | 1 | 2023 | 82 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2024 | 660 | 0.050 |
Why?
|
| Computational Biology | 1 | 2024 | 367 | 0.050 |
Why?
|
| Adolescent | 3 | 2024 | 6296 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 76 | 0.040 |
Why?
|
| Mothers | 1 | 2025 | 281 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1282 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2026 | 3139 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 39 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2022 | 224 | 0.040 |
Why?
|
| Inflammation Mediators | 2 | 2012 | 179 | 0.040 |
Why?
|
| Bottle Feeding | 1 | 2019 | 6 | 0.040 |
Why?
|
| Infant Formula | 1 | 2019 | 13 | 0.040 |
Why?
|
| Breast Milk Expression | 1 | 2019 | 8 | 0.040 |
Why?
|
| Nutritive Value | 1 | 2019 | 37 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 497 | 0.040 |
Why?
|
| Enteral Nutrition | 1 | 2019 | 53 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 386 | 0.040 |
Why?
|
| Communication | 1 | 2024 | 597 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 4811 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 194 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 92 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2025 | 2098 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2012 | 2186 | 0.030 |
Why?
|
| Cell Line | 2 | 2012 | 2018 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1113 | 0.030 |
Why?
|
| Middle Aged | 3 | 2024 | 18252 | 0.030 |
Why?
|
| Receptors, Neurotensin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Uncoupling Agents | 1 | 2012 | 5 | 0.020 |
Why?
|
| Oligomycins | 1 | 2012 | 4 | 0.020 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Neuropeptides | 1 | 2012 | 81 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 70 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 95 | 0.020 |
Why?
|
| Dynamins | 1 | 2011 | 13 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2011 | 38 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2012 | 162 | 0.020 |
Why?
|
| Exocytosis | 1 | 2011 | 61 | 0.020 |
Why?
|
| Calcineurin | 1 | 2011 | 48 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 432 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2011 | 80 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 139 | 0.020 |
Why?
|
| GTP Phosphohydrolases | 1 | 2011 | 64 | 0.020 |
Why?
|
| Antigens | 1 | 2011 | 145 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 116 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 87 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 109 | 0.020 |
Why?
|
| Interleukin-33 | 1 | 2010 | 19 | 0.020 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2010 | 24 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2010 | 80 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 219 | 0.020 |
Why?
|
| Piperidines | 1 | 2010 | 72 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 961 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 511 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2012 | 616 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 454 | 0.020 |
Why?
|
| Cytosol | 1 | 2010 | 182 | 0.020 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 225 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 324 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1140 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 894 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 1560 | 0.020 |
Why?
|
| Anxiety | 1 | 2010 | 425 | 0.020 |
Why?
|
| Lung | 1 | 2012 | 964 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 553 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 1445 | 0.020 |
Why?
|
| Aged | 1 | 2022 | 14949 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 1219 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1628 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 981 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 2703 | 0.010 |
Why?
|